Classifica tra le azioni
#2843
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops... CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Prezzo delle azioni
$78.86
Capitalizzazione di mercato
$6.96B
Variazione (1 giorno)
0.80%
Variazione (1 anno)
210.23%
Scambia CG Oncology Inc. (CGON)
EPS per CG Oncology Inc. (CGON)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di CG Oncology Inc., l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per CG Oncology Inc. da 2026 a 2026
EPS alla fine di ogni anno
| Anno |
EPS |
Cambia |
|
Non abbastanza dati per le date fornite. |
EPS per aziende simili o concorrenti
| Azienda |
EPS |
Differenza di EPS |
Il paese |
|
|
$17.32 |
-
|
US
|
|
|
$27.74 |
-
|
NL
|
|
|
$-7.98 |
-
|
US
|
|
|
$-5.29 |
-
|
AU
|
|
|
- |
-
|
CH
|
